Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Associate Professor Ross Chapman joins us along with his research group from the 1st of June 2020.

The Chapman group in the laboratory.

A warm welcome to the Chapman group, who join us from the Wellcome Trust Centre for Human Genetics, where they have been studying the DNA repair mechanisms that allow for programmed genome diversification in the immune system, and have identified these same mechanisms to be responsible for cancer development and its response to treatment.

A key objective of the group, led by Ross, is to understand the context-specificity of the different DNA double-stranded break (DSB) repair systems, and the regulatory mechanisms that ensure DNA breaks are appropriately channelled to either accurate or mutagenic repair outcomes in different tissues and cellular contexts.

MRC WIMM Director Professor KJ Patel said “I am delighted to welcome Ross Chapman and his group to the MRC WIMM. I hope that the Institute will provide an environment within which their research into DNA repair mechanisms in cancer and genome diversification can flourish. We look forward to welcoming Ross and his team in person once we are safely back in the building.”

Ross Chapman said “My team and I are very excited by this move to the Institute and are very much looking forward to getting settled into working in the building. For a long time, I’ve admired the inspiring research and strong ethos at the MRC WIMM from the outside, so it’s great that we can now contribute and be part of this. We look forward to getting to know all the people that make up the MRC WIMM community, and to embarking on exciting collaborations with other teams.”

Ross completed his PhD at the University of Cambridge in 2010, before moving to Cancer Research UK Clare Hall Laboratories where he undertook the majority of his Sir Henry Welcome Postdoctoral Fellowship training. In 2013, he moved to Oxford and established his group at the Wellcome Trust Centre for Human Genetics. He is a Lister Fellow, Cancer Research UK Career Development Fellow, and EMBO Young Investigator.